Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390780 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients
A Phase 3 study, sponsored by Valerio Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 578
- Enrollment target
NCT00390780 is a Phase 3 study that has completed, run by Valerio Therapeutics. The registered enrollment target is 578 participants.
The verdict
NCT00390780, a Phase 3 study, has completed, sponsored by Valerio Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 578 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical cure of miconazole Lauriad 50 mg (1x50mg) Bioadhesive buccal tablets compared with clotrimazole troches (5x10mg) after 14 days of treatment (at the test of cure visit, at Day 17-19).
Interventions
- DRUG Clotrimazole
- DRUG miconazole Lauriad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390780
The ClinicalTrials.gov registry entry for NCT00390780 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 578 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clotrimazole is the first listed.
NCT00390780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00390780 about?
NCT00390780 is a clinical study titled "Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients". The purpose of this study is to evaluate the clinical cure of miconazole Lauriad 50 mg (1x50mg) Bioadhesive buccal tablets compared with clotrimazole troches (5x10mg) after 14 days of treatment (at the test of cure visit, at Day 17-19).
What is the current status of trial NCT00390780?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 578 participants. The study started on 2006-07. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00390780?
The interventions under investigation include: Clotrimazole (DRUG), miconazole Lauriad (DRUG).
Who is sponsoring clinical trial NCT00390780?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.